How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily
- How Two Rivals Undercut J&J's Beat And Big Guidance Investor's Business Daily
- What you need to know about Johnson & Johnson’s fourth-quarter and full-year 2025 earnings report Johnson & Johnson
- J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025. MarketWatch
- J&J’s cardiovascular business boosts medtech growth in 2025 MedTech Dive
- Johnson & Johnson forecasts 2026 profit above Wall Street estimates CNBC